Looking at top Wall Street opinions, Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has recently made its way into the research list of Needham – signaling that their analyst’s rating adjustment is noteworthy. This stock was Reiterated to a rating of Buy in the eyes of Needham, as reported on Friday, July 13th, 2018. Another heavy-hitting research note was published by H.C. Wainwright on Friday February 16th, 2018, with this firm Resumed AERI to an updated rating of Buy. In the past six months and three months of trading, shares of Aerie Pharmaceuticals, Inc. (AERI) have moved by -37.37% and -21.03%, respectively.
Brokerage Updates Related to Aerie Pharmaceuticals, Inc. (AERI) Stock
This publicly-traded organization generated losses of -15.16% over the last 5 sessions. Right now, this stock is the subject of 11 analysts’ evaluations, who – on average – have given this company’s shares a Strong Buy rating. Not a Single analyst have given underperform rating or sell rating, and 4 have given a rating of Buy or better. Based on the 11 stock market experts following this company, the average 12-month price target is $83.10. Moreover, individual price targets range between $64.00-$105.00. With its recent move to $84.00, we can see that these firms project this stock will loss by -24.74% in one year.
Updates from Aerie Pharmaceuticals, Inc. (AERI) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 1.10% rise since the beginning of the calendar year. A Chief Scientific Officer at Aerie Pharmaceuticals, Inc. (AERI) sold off some of its shares in a transaction that was finalized on Feb 01. Similarly, Kopczynski Casey C. sold 11,000 shares of the organization’s stock at $35.21 apiece and racked up $387,313 in earnings from the sale. Now, Kopczynski Casey C. holds 106,743 shares of the company following the exchange. A Chief Scientific Officer of the organization named Kopczynski Casey C., was engaged in a transaction that occurred on Dec 03 that managed to be worth $437,894 from the sale of 11,000 common shares at a price of $39.81 per individual share.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Results in the Pipeline
The next scheduled release of financial results for Aerie Pharmaceuticals, Inc. will be for the Sep-18 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be -$1.38. In the same vein, they expect sales for the quarter to amount to $5.88 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $7.30 million in revenue alongside EPS at -$1.73. On average, the analyst projection was calling for $2.42 million with -$1.14 per share in earnings, respectively.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) experienced a drop of -2.32% from the closing price in the previous trading day. That drove the price to $21.48 per share, as observed on February 11th, 2019, at a time when the total trading volume reached 2,000,086 shares of stock – compared to the typical average of 1.98M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $31.55.
Pricing Indications for ACADIA Pharmaceuticals Inc. (ACAD)
This organization has had a price-to-earnings ratio of in the last year. In the most recent trading session, the daily high was $22.49, bringing the per-share value -2.32% high its 52-week high and about -33.97% more expensive than its 52-week low. Meanwhile, it gained 19.45 from its observable 50-day simple moving average. Right at this moment, the per-share value is 19.84% higher than the mean per-share price over the last 200 days in the market.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 1 have a Buy rating, 7 have an outperform rating, while 4 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 2.30, based on information from Thomson Reuters.
ACAD Stock Value Potential
In trading activity as of late, this stock’s value was 17.95 up from its 200 day moving average, while also 10.93% up when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $20.00-$60.00. The market value for the entire organization reached 3.08B. After the trading day started off at the price of $21.48, these shares nearly bottomed out at its low price of $21.035 and nearly peaked at $22.49 as its full-day high price. In the last trading session, the price ended the day at $21.99. The institutional holdings related to this organization account for 0.10%, and the Beta factor is now 3.28. This company’s RSI (Relative Strength Index) managed to hit 51.01.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Analyst Points of Focus
ACADIA Pharmaceuticals Inc. (ACAD) has found itself inside of Canaccord Genuity’s research list, so their analyst rating adjustment is worth taking note of. This stock was Initiated to Hold, by Canaccord Genuity, as garnered from a news report on Monday December 10th, 2018. An additional helpful research note was sent out by Piper Jaffray’s on Friday September 21st, 2018. The brokerage decided to upgrade ACAD to Overweight from its previous rating of Neutral.